Clinical Report: Significant Recovery with Upadacitinib in SAPHO Syndrome
Overview
This report details a case of a 42-year-old man with SAPHO syndrome who experienced significant recovery of paradoxical skin lesions after switching from adalimumab to upadacitinib. The treatment led to rapid improvement in skin lesions and sustained control of musculoskeletal symptoms without adverse events.
Background
SAPHO syndrome is a rare autoinflammatory disorder characterized by osteoarticular and skin manifestations, presenting significant therapeutic challenges. Paradoxical skin lesions have been reported during treatment with TNF-α inhibitors, complicating management. Understanding alternative treatment options, such as Janus kinase inhibitors, is crucial.
Data Highlights
No numerical data or trial data presented in the article.
Key Findings
A 42-year-old man with SAPHO syndrome had chronic pain and skin lesions.
Conventional therapy with etoricoxib and methotrexate improved pain but not skin lesions.
Adalimumab treatment worsened the skin lesions after three months.
Switching to upadacitinib resulted in marked improvement of skin lesions and symptom relief.
No adverse events were reported during upadacitinib therapy.
Clinical Implications
This case presents a patient with SAPHO syndrome experiencing paradoxical skin lesions due to TNF-α inhibitors.
Conclusion
This case presents findings on the use of Janus kinase inhibitors in managing paradoxical skin lesions in SAPHO syndrome.
